Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635800 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
A Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 6
- Study locations
NCT04635800 is a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 21 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04635800, a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 6
- Study locations
Study Summary
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
Conditions Studied
Interventions
- DRUG MHU650
Study Locations (6)
Texas
- Novartis Investigative Site - Austin
- Novartis Investigative Site - Houston
California
- Novartis Investigative Site - Huntington Beach
Hawaii
- Novartis Investigative Site - Honolulu
Maryland
- Novartis Investigative Site - Hagerstown
Other
- Novartis Investigative Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04635800
The ClinicalTrials.gov registry entry for NCT04635800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which MHU650 is the first listed.
NCT04635800 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Hawaii.
Frequently Asked Questions
What is clinical trial NCT04635800 about?
NCT04635800 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients". This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
What is the current status of trial NCT04635800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-12-10. Estimated completion is 2022-05-24.
What conditions does trial NCT04635800 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion.
What interventions are being tested in trial NCT04635800?
The interventions under investigation include: MHU650 (DRUG).
Who is sponsoring clinical trial NCT04635800?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04635800 being conducted?
This trial has 6 study locations across California, Hawaii, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Explore more on PlainTrial
Diabetic Macular Edema
All registered trials for this condition
Neovascular Age-related Macular Degeneration
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.